Literature DB >> 33502903

Lymphatic Vasculature: An Emerging Therapeutic Target and Drug Delivery Route.

Wenjing Xu1, Natalie R Harris1, Kathleen M Caron1.   

Abstract

The lymphatic system has received increasing scientific and clinical attention because a wide variety of diseases are linked to lymphatic pathologies and because the lymphatic system serves as an ideal conduit for drug delivery. Lymphatic vessels exert heterogeneous roles in different organs and vascular beds, and consequently, their dysfunction leads to distinct organ-specific outcomes. Although studies in animal model systems have led to the identification of crucial lymphatic genes with potential therapeutic benefit, effective lymphatic-targeted therapeutics are currently lacking for human lymphatic pathological conditions. Here, we focus on the therapeutic roles of lymphatic vessels in diseases and summarize the promising therapeutic targets for modulating lymphangiogenesis or lymphatic function in preclinical or clinical settings. We also discuss considerations for drug delivery or targeting of lymphatic vessels for treatment of lymphatic-related diseases. The lymphatic vasculature is rapidly emerging as a critical system for targeted modulation of its function and as a vehicle for innovative drug delivery.

Entities:  

Keywords:  VEGF-C; adrenomedullin; drug delivery; lymphangiogenesis; lymphatics

Year:  2021        PMID: 33502903     DOI: 10.1146/annurev-med-051419-114417

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  6 in total

Review 1.  The bright future of nanotechnology in lymphatic system imaging and imaging-guided surgery.

Authors:  Shaolong Qi; Xinyu Wang; Kun Chang; Wenbin Shen; Guocan Yu; Jianshi Du
Journal:  J Nanobiotechnology       Date:  2022-01-06       Impact factor: 10.435

Review 2.  Advances in Drugs Targeting Lymphangiogenesis for Preventing Tumor Progression and Metastasis.

Authors:  Chuqi Wang; Ming Chu
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

3.  A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy.

Authors:  Brian D Ross; Youngsoon Jang; Amanda Welton; Christopher A Bonham; Dilrukshika S W Palagama; Kevin Heist; Jagadish Boppisetti; Kasun P Imaduwage; Tanner Robison; Leah R King; Edward Z Zhang; Cyrus Amirfazli; Kathryn E Luker; Winston Y Lee; Gary D Luker; Thomas L Chenevert; Marcian E Van Dort
Journal:  Nat Commun       Date:  2022-08-17       Impact factor: 17.694

Review 4.  Nanomaterial-Based Drug Delivery System Targeting Lymph Nodes.

Authors:  Zesheng Cheng; Haiying Que; Li Chen; Qiu Sun; Xiawei Wei
Journal:  Pharmaceutics       Date:  2022-06-28       Impact factor: 6.525

5.  Lymphangiogenesis requires Ang2/Tie/PI3K signaling for VEGFR3 cell-surface expression.

Authors:  Emilia A Korhonen; Aino Murtomäki; Sawan Kumar Jha; Andrey Anisimov; Anne Pink; Yan Zhang; Simon Stritt; Inam Liaqat; Lukas Stanczuk; Laura Alderfer; Zhiliang Sun; Emmi Kapiainen; Abhishek Singh; Ibrahim Sultan; Anni Lantta; Veli-Matti Leppänen; Lauri Eklund; Yulong He; Hellmut G Augustin; Kari Vaahtomeri; Pipsa Saharinen; Taija Mäkinen; Kari Alitalo
Journal:  J Clin Invest       Date:  2022-08-01       Impact factor: 19.456

Review 6.  In Vitro, In Vivo, and In Silico Models of Lymphangiogenesis in Solid Malignancies.

Authors:  Sophie Bekisz; Louis Baudin; Florence Buntinx; Agnès Noël; Liesbet Geris
Journal:  Cancers (Basel)       Date:  2022-03-16       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.